Oruka Therapeutics (ORKA) Price Target Increased to $120 by Leerink

Leerink Partners raised the price target for Oruka Therapeutics, Inc. (ORKA) to $120 from $109 on April 30, maintaining an Outperform rating. On April 27, ORKA announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, revealing a 63.5% response rate at Week 16 for moderate-to-severe plaque psoriasis. The trial's favorable safety profile aligns with the IL-23p19 class of therapies. Long-term data from this study is expected in H2 2026, which may influence investor sentiment toward ORKA and its pipeline of monoclonal antibodies.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.